Cigna executives kicked off Thursday’s earnings call by responding to pharmacy benefit manager critics with a number of reforms.

Management projects 2025 adjusted EPS of at least $29.50, supported by biosimilar growth and strategic investments. Full-year consolidated adjusted revenue is expected to exceed $252 billion.

CVS's app is designed as a one-stop shop for customers to do everything from manage prescriptions to opening locked display ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Fresh off underperforming Wall Street’s expectations in the fourth quarter, Cigna said it would work to lower costs for its ...

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.